OncoMatch/Clinical Trials/NCT05241093
A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Is NCT05241093 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies HYML-122; cytarabine for relapsed or refractory acute myeloid leukemia (aml).
Treatment: HYML-122; cytarabine — This is a single-arm, open, multicenter, phase 2 study to evaluate the efficacy, safety and pharmacokinetics of HYLM-122 in combination with cytarabine in Chinese subjects with FLT3 positive relapsed or refractory acute myeloid leukemia.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: FLT3 mutation
Disease stage
Required: Stage RELAPSED, REFRACTORY
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: induction chemotherapy
Refractory to at least 1 cycle of induction chemotherapy. Relapsed after achieving remission with a prior therapy.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify